NASDAQ$NKTX
Nkarta Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Nkarta reported financial results for the fourth quarter and year ended December 31, 2021.
Nkarta reports a net loss of $22.8 million, or $0.69 per basic and diluted share, for the fourth quarter of 2021. As of December 31, 2021, Nkarta had cash, cash equivalents, restricted cash and short-term investments of $240.2 million.
- On track to announce initial Phase 1 clinical trial data from two co-lead programs in 2022
- NKX101 received orphan drug designation (ODD) for the treatment of acute AML from the FDA in December 2021.
- Nkarta is producing clinical supply of NKX019 at its in-house cGMP clinical manufacturing facility in South San Francisco, California.
- Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023.
Headline financials
Revenue & EPS history
Nkarta · Revenue · Quarterly
$0
Forward guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+0.4%
Avg return
Earnings day
-2.5%
Avg return
5 days after
+1.4%
Avg return
30 days after
61%
14 / 23 earnings
Positive
+16.2%
Q4 2021
Best reaction
-30.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.5% | -16.1% | — | |
| Q4 2025 | +0.9% | -0.9% | +37.1% | |
| Q3 2025 | +3.1% | -4.6% | -4.6% | |
| Q1 2025 | +1.2% | -0.6% | -4.6% | |
| Q4 2024 | +3.2% | -15.4% | +13.3% | |
| Q3 2024 | -4.8% | -9.0% | -23.0% | |
| Q2 2024 | +1.2% | +0.0% | +10.3% | |
| Q1 2024 | -2.3% | +2.3% | +3.1% | |
| Q4 2023 | -30.3% | -22.8% | -43.0% | |
| Q3 2023 | -5.6% | +7.0% | +27.0% | |
| Q2 2023 | -0.5% | -1.0% | -20.5% | |
| Q1 2023 | -4.1% | -4.1% | -0.9% | |
| Q4 2022 | +1.3% | -7.1% | +19.3% | |
| Q3 2022 | -8.4% | -2.1% | -35.5% | |
| Q2 2022 | +8.8% | +11.1% | -8.5% | |
| Q1 2022 | +12.8% | +11.1% | +6.9% | |
| Q4 2021 | +16.2% | +6.2% | -15.2% | |
| Q3 2021 | +7.7% | +7.2% | -15.0% | |
| Q2 2021 | -1.9% | -5.0% | -29.0% | |
| Q4 2020 | +0.0% | -14.4% | -30.3% | |
| Q3 2020 | +2.9% | +14.5% | +122.0% | |
| Q2 2020 | -7.0% | -12.0% | +21.1% | |
| Q1 2021 | +11.3% | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro